CXCL3 silencing inhibited tumor growth in the CD133+ population, although there was no significant difference in the tumor mass between CD133+-shCXCL3 and CD133− cells groups (Fig. 2e), suggesting that CXCL3 promoted CD133+ HCC CSC maintenance in vivo. This evidence concerns the gene CXCL3 and neoplasm.